Genmab — November 2020
-
Analytiker øjner opjustering fra Genmab
Der kan være en opjustering på vej fra medicinalselskabet Genmab, der onsdag fremlægger sine tal for tredje kvartal, vurderer Sydbank på baggrund af tal fra partneren Johnson & Johnson, som allerede for mere end 14 dage siden løftede sløret for et bedre end ventet salg af kræftmidlet Darzalex.
(medwatch.dk)
-
Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM) https://ashpublications.org/blood/article/136/Supplement 1/27/469910/Updated-Phase-1-Results-of-Teclistamab-a-B-Cell?searchresult=1
-
Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models https://ashpublications.org/blood/article/136/Supplement 1/19/471645/Preclinical-Anti-Tumor-Activity-of-Hexabody-CD38?searchresult=1
-
GEN3013 -
Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo, Irrespective of Prior Treatment with CD20 Monoclonal Antibodies https://ashpublications.org/blood/article/134/Supplement_1/4066/424296/Duobody-CD3xCD20-Induces-Potent-Anti-Tumor?searchresult=1 -
First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody
-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas https://ashpublications.org/blood/article/134/Supplement_1/758/426903/First-in-Human-Phase-1-2-Trial-to-Assess-the?searchresult=1 -
Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo, and Is Being Evaluated Clinically in Patients with B-Cell Malignancies https://ashpublications.org/blood/article/132/Supplement 1/1664/273265/Duobody-CD3xCD20-Shows-Unique-and-Potent?searchresult=1
-
Immunoprofiling of Normal Human Donor Blood Identified Potential Pharmacodynamic Markers for JNJ-63709178 (CD123xCD3) Duobody
Antibody Treatment https://ashpublications.org/blood/article/128/22/5215/100049/Immunoprofiling-of-Normal-Human-Donor-Blood?searchresult=1 -
A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) https://ashpublications.org/blood/article/136/Supplement 1/40/470139/A-Phase-1-First-in-Human-Study-of-Talquetamab-a-G?searchresult=1
-
-
that is a good point. the PhII is also SC https://clinicaltrials.gov/ct2/history/NCT04557098?A=1&B=2&C=merged#StudyPageTop
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind